文献速递泌尿生殖介入MRCT

前列腺质子放疗中对多参数MRI定义的优势前列腺内病灶进行局灶剂量提升的规划研究

A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
PubMed 文献 · Br J Radiol · 2020-01-06

回顾性分析36例接受铅笔束扫描质子全前列腺放疗患者,基于多参数MRI勾画优势前列腺内病灶并制定同步整合 boost 的调强质子治疗计划。优化后 boost 计划在不违反危及器官约束下显著提升病灶剂量,模型显示病灶肿瘤控制概率增加7.3%至13.3%。作者认为该策略可行且可能改善肿瘤控制。

要点

  • 多参数MRI可勾画前列腺内优势病灶,质子同步整合 boost 能在满足危及器官约束下实现病灶剂量提升。
  • 36例中分别有74%、54%、17%的病例达到处方剂量125%、150%、175%的病灶覆盖。
  • 模型估计病灶肿瘤控制概率增加7.3%至13.3%,取决于α/β值和病灶风险等级。

核心结论

  • 基于多参数MRI引导的前列腺质子放疗病灶 boost 在不违反危及器官约束的前提下可行,并可能通过提高病灶肿瘤控制概率带来临床获益。

研究设计与样本

  • 回顾性规划研究,纳入36例有治疗前多参数MRI和CT图像、接受铅笔束扫描质子全前列腺放疗的患者;在配准的多参数MRI上勾画优势前列腺内病灶,基于常规全前列腺照射为每例创建调强质子治疗同步整合 boost 计划,并额外优化病灶覆盖目标和尿道约束。

诊断标准与关键数值

  • 优化后的同步整合 boost 计划在36例中分别有74%、54%、17%的病例达到处方剂量125%、150%、175%的病灶覆盖;模型估计病灶肿瘤控制概率增加7.3%至13.3%,取决于α/β值和病灶风险等级。

临床应用与阅片要点

  • 作者认为基于调强质子治疗的病灶同步整合 boost 可能代表一种改善肿瘤控制的策略;研究比较了常规计划与同步整合 boost 计划的病灶剂量覆盖和危及器官保护,并估计了肿瘤控制概率和正常组织并发症概率。

局限性

  • 原文为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study is to investigate the dosimetric effect and clinical impact of delivering a focal radiotherapy boost dose to multiparametric MRI (mp-MRI)-defined dominant intraprostatic lesions (DILs) in prostate cancer using proton therapy.

METHODS: We retrospectively investigated 36 patients with pre-treatment mp-MRI and CT images who were treated using pencil beam scanning (PBS) proton radiation therapy to the whole prostate. DILs were contoured on co-registered mp-MRIs. Simultaneous integrated boost (SIB) plans using intensity-modulated proton therapy (IMPT) were created based on conventional whole-prostate-irradiation for each patient and optimized with additional DIL coverage goals and urethral constraints. DIL dose coverage and organ-at-risk (OAR) sparing were compared between conventional and SIB plans. Tumor control probability (TCP) and normal tissue complication probability (NTCP) were estimated to evaluate the clinical impact of the SIB plans.

RESULTS: Optimized SIB plans significantly escalated the dose to DILs while meeting OAR constraints. SIB plans were able to achieve 125, 150 and 175% of prescription dose coverage in 74, 54 and 17% of 36 patients, respectively. This was modeled to result in an increase in DIL TCP by 7.3-13.3% depending on α/β and DIL risk level.

CONCLUSION: The proposed mp-MRI-guided DIL boost using proton radiation therapy is feasible without violating OAR constraints and demonstrates a potential clinical benefit by improving DIL TCP. This retrospective study suggested the use of IMPT-based DIL SIB may represent a strategy to improve tumor control.

ADVANCES IN KNOWLEDGE: This study investigated the planning of mp-MRI-guided DIL boost in prostate proton radiation therapy and estimated its clinical impact with respect to TCP and NTCP.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Wang T, Zhou J, Tian S, et al. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy. Br J Radiol. 2020. PMID: 31904261. doi:10.1259/bjr.20190845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。